Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
July 14 2022 - 8:00AM
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean
Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter,
Senior Scientist, each will present data from the company’s
COVID-19 oral tablet vaccine development program at the
International Congress of Mucosal Immunology 2022, which is being
held in Seattle July 16 to 20, 2022.
Presentation Information:
Title: Oral Tablet Vaccination to SARS-CoV-2
Induces Pan-coronavirus Nasal IgA Responses in
HumansSpeaker: Dr. Sean
TuckerDate: Monday, July 18,
2022Time: 11:00 a.m. PT / 2:00 p.m. ET
Title: Mucosal rAd5 Immunization against
SARS-CoV-2 Spike Elicits Cross-Reactive Nasal and Serum
Neutralizing Antibodies and Protects Against Beta Variant Challenge
in Non-Human Primates Speaker: Dr. Rebecca
FlitterDate: Monday, July 18, 2022
Time: 11:00 a.m. PT / 2:00 p.m. ET
About VaxartVaxart is a clinical-stage
biotechnology company developing a range of oral recombinant
vaccines based on its proprietary delivery platform. Vaxart
vaccines are designed to be administered using tablets that can be
stored and shipped without refrigeration and eliminate the risk of
needle-stick injury. Vaxart believes that its proprietary tablet
vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart’s development programs currently include
tablet vaccines designed to protect against coronavirus, norovirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immune-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Contacts
Vaxart Media
Relations: |
Investor
Relations: |
Mark Herr |
Andrew Blazier |
Vaxart,
Inc. |
FINN Partners |
mherr@vaxart.com |
IR@Vaxart.com |
(203)
517-8957 |
(646)
871-8486 |
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024